Summary
Alefacept has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Psoriasis (Nail / Palmoplantar) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Psoriasis (Nail / Palmoplantar). No registered clinical trial in this database tests Alefacept specifically in Psoriasis (Nail / Palmoplantar). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2005 to 2007. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Psoriasis Vulgaris ranks 242 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous PASI90 remission essentially zero without treatment; natural fluctuation occurs but complete clearance rare; <5% achieve sustained spontaneous remission over 5 years.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 24.0 (trials 0.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | CD2 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Alefacept to Psoriasis (Nail / Palmoplantar) in the current OSMF trial extract.
Published literature
- Clinical trial publication Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasisChamian F, Lin SL, Lee E et al. · Journal of translational medicine · 2007 · PMID 17555598
- Clinical trial publication Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgarisChamian F, Lowes MA, Lin SL et al. · Proceedings of the National Academy of Sciences of the United States of America · 2005 · PMID 15671179
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Alefacept approved for Psoriasis (Nail / Palmoplantar)?
Alefacept has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Psoriasis (Nail / Palmoplantar) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Psoriasis (Nail / Palmoplantar). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Alefacept in clinical trials for Psoriasis (Nail / Palmoplantar)?
No registered clinical trial in this database tests Alefacept specifically in Psoriasis (Nail / Palmoplantar). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Alefacept in Psoriasis (Nail / Palmoplantar)?
The record for Alefacept in Psoriasis (Nail / Palmoplantar) rests on 2 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.